Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MECP2 | P51608 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.47 |
| ▸ | DHODH | Q02127 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PLEC | Q15149 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207474 | 0.87 | RECQL (0.50) | KMT2AMEN1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL4478341 | 0.84 | CDC25B (0.52) | KMT2AMEN1MAPTSMN1; SMN2LMNA | |
| SCHEMBL5207273 | 0.81 | AKR1C3 (0.46) | KMT2AMEN1MAPTTP53SMN1; SMN2 | |
| SCHEMBL4490345 | 0.81 | FABP3 (0.51) | KMT2AMEN1MAPTTP53SMN1; SMN2 | |
| SCHEMBL4484788 | 0.80 | AKR1C3 (0.46) | MAPTTP53SMN1; SMN2LMNAHPGD | |
| SCHEMBL4491211 | 0.79 | ALDH1A1 (0.47) | KMT2AMEN1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL4482947 | 0.79 | AKR1C3 (0.58) | KMT2AMEN1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL4495216 | 0.78 | CXCR5 (0.46) | KMT2AMEN1MAPTTP53SMN1; SMN2 | |
| SCHEMBL5206781 | 0.78 | MEN1 (0.45) | KMT2AMEN1MAPTMAPK1LMNA | |
| SCHEMBL4487791 | 0.78 | KDM4E (0.53) | KMT2AMEN1MAPTMAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372654-A4 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SMITHKLINE BEECHAM CORP (US) | 2007-10-03 | — | — | EP | claimed |
| US-7087758-B2 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-08 | — | — | US | claimed |
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | claimed |
| EP-1372654-A2 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2002081728-A2 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-17 | — | — | WO | claimed |
| EP-1372654-A4 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SMITHKLINE BEECHAM CORP (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7087758-B2 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| EP-1372654-A2 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002081728-A2 | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | HIPK3, HIPK1, HYPK | KMT2A 1719/4885MEN1 2633/4885MAPT 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.